Skip to main content
. 2015 Jul 2;6(28):26278–26290. doi: 10.18632/oncotarget.4495

Figure 4. Inhibition of the MAPK pathway reduces MGL ligand binding.

Figure 4

HT29 cells were either mock- (DMSO) treated or treated with the MEK inhibitor (U0126) or the BRAFV600E inhibitors PLX4032 (Vemurafenib) or PLX4720 (25 μM each). A. After a 4 hr treatment, HT29 cells were analyzed for intracellular phospho-ERK1/2 levels by flow cytometry. Representative flow cytometry plots are shown. Filled histograms indicates the phospho-ERK1/2 staining, solid line represents the isotype control. B. HT29 cells were incubated for 24 hrs with the inhibitors and analyzed for MGL-Fc and HPA-binding using flow cytometry. MGL-binding in the presence of EGTA was used to normalize the signal, HPA-binding was normalized to the negative control, binding is displayed as relative binding compared to mock-treated cells. Data are combined results of four independent experiments.